Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

Rationale There is no consensus as to when treatment for idiopathic pulmonary fibrosis (IPF) should be initiated. Some physicians prefer not to treat patients with preserved lung volume. Objective To investigate whether patients with IPF and preserved lung volume receive the same benefit from nintedanib as patients with more impaired lung volume. Methods Post hoc subgroup analyses of pooled data from the two replicate phase III INPULSIS trials by baseline FVC % predicted (90%). Results At baseline, 274 patients had FVC >90% predicted and 787 patients had FVC 90% predicted and FVC 90% predicted and 90% predicted) have the same rate of FVC decline and receive the same benefit from nintedanib as patients with more impaired lung volume